Use of hyoscine-n-butylbromide, carbon dioxide gas, position change and rectal retroflexion
| SC (n=884) | EAC (n=888) | % Difference (one-sided 97.5% CI) | One-sided P value | |
| Hyoscine-n-butylbromide use | ||||
| Global | 568 (64.3%) | 627 (70.6%) | 6.4% (2.7% to ∞) | 0.002 |
| Non-BCSP | 259 (53.9%) | 327 (66.2%) | 12.3% (7.2% to ∞) | <0.001 |
| BCSP | 309 (76.7%) | 300 (76.1%) | −0.5% (−5.5% to ∞) | 0.57 |
| Carbon dioxide gas use | ||||
| Global | 678 (76.7%) | 672 (75.7%) | −1.0% (−4.3% to ∞) | 0.69 |
| Non-BCSP | 311 (64.7%) | 315 (63.8%) | −0.9% (−5.9% to ∞) | 0.61 |
| BCSP | 367 (91.1%) | 357 (90.6%) | −0.5% (−3.8% to ∞) | 0.59 |
| Position change | ||||
| Global | 772 (87.5%) | 718 (81.3%) | −6.2% (−9.0% to ∞) | 1.00 |
| Non-BCSP | 413 (86.0%) | 392 (79.8%) | −6.2% (− 10.2% to ∞) | 0.99 |
| BCSP | 359 (89.3%) | 326 (83.2%) | −6.1% (−10.2% to ∞) | 0.99 |
| Rectal retroflexion | ||||
| Global | 785 (88.8%) | 723 (81.4%) | −7.4% (−10.1% to ∞) | 1.00 |
| Non-BCSP | 422 (87.7%) | 401 (81.2%) | −6.6% (−10.4% to ∞) | 1.00 |
| BCSP | 363 (90.1%) | 322 (81.7%) | −8.3% (−12.4% to ∞) | 1.00 |
BCSP, Bowel Cancer Screening Programme; EAC, EV-assisted colonoscopy; SC, standard colonoscopy.